Product Description
Mechanisms of Action: 5-HT4 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Gastroesophageal Reflux|Esophagitis, Peptic|Heartburn|Bile Reflux
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SPD557-206 | P2 |
Completed |
Bile Reflux|Gastroesophageal Reflux|Heartburn |
2013-05-14 |
|
SPD557-206 | P2 |
Completed |
Gastroesophageal Reflux|Esophagitis, Peptic |
2013-05-14 |
|
SPD557-107 | P1 |
Completed |
Healthy Volunteers |
2013-04-12 |
|
SPD557-202 | P2 |
Terminated |
Gastroesophageal Reflux |
2012-05-29 |